Clinical trial NCT01473628: Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma
Official title: Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Ann Arbor Stage I Grade 1 Follicular Lymphoma
Ann Arbor Stage I Grade 2 Follicular Lymphoma
Ann Arbor Stage II Grade 1 Follicular Lymphoma
Ann Arbor Stage II Grade 2 Follicular Lymphoma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2011-11-17
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized phase I/II trial studies radiation therapy and rituximab in treating patients with stage I-II grade 1 or grade 2 follicular lymphoma. Radiation therapy uses high energy x-rays to kill cancer cells. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy with rituximab may kill more cancer cells.

Detailed description: PRIMARY OBJECTIVE:

I. To determine if rituximab concurrently with radiation followed by maintenance rituximab offers a superior benefit over radiation alone. Specifically looking at the progression free survival.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab intravenously (IV) over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.

After completion of study treatment, patients are followed up at 3 and 6 months, every 6 months for 2 years, yearly for 3 years, and then every 2 years for 10 years.

Eligibility criteria: Inclusion Criteria:

* Newly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade 1 or 2
* Prophylactic use of lamivudine in patients that have antibody positive (+), but no active infection will be up to the treating physician
* Absolute neutrophil count (ANC) \>= 1000/mm\^3; this value must be obtained within four weeks before protocol entry
* Platelets \>= 80,000/mm\^3; this value must be obtained within four weeks before protocol entry
* Hemoglobin \>= 8 g/dL; this value must be obtained within four weeks before protocol entry
* Bilirubin =\< 1.5 times the upper limit of normal (ULN); this value must be obtained within four weeks before protocol entry
* Alanine aminotransferase (ALT) =\< 2 times the ULN or aspartate aminotransferase (AST) =\< 2 times the ULN; these values must be obtained within four weeks before protocol entry
* Performance status \>= 2
* Patients are required to have adequate renal function as indicated by a serum creatinine =\< 2.5 mg/dL; this value must be obtained within four weeks before protocol entry
* No prior known allergic reaction to monoclonal antibodies
* Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study
* Female patients must be willing to use two adequate barrier methods of contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study or be post menopausal (free from menses \> two years or surgically sterilized)
* Female patients of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin \[B HCG\]) within 72 hours of receiving the first dose of rituximab
* Patients must have the ability able to give informed consent

Exclusion Criteria:

* Patients with active hepatitis B and/or hepatitis C infection
* Patients with known human immunodeficiency virus (HIV) infection
* Patients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolved
* Patients who had previous radiation dose to the site of the current primary disease, which would lead to violation of known radiation tolerance limit of that particular site if treated again
* Patients with pre-existing cardiovascular disease requiring ongoing treatment; this includes: congestive heart failure III/IV as defined by New York Heart Association (NYHA); uncontrolled cardiac arrhythmia; unstable angina pectoris; and recent myocardial infarction (MI) (within 6 months)
* Patients who are pregnant or breast-feeding
* Patient with concurrent use of complementary or alternative medicines
* Patients with psychiatric illness and/or social situations that would limit compliance with the study medication and requirements

Primary outcomes:
measure: Proportion of patients that remain progression free, defined as progressive disease or death due to disease
timeFrame: Up to 15 years
Secondary outcomes:
measure: Overall survival
timeFrame: Up to 15 years
measure: Progression free survival rate
timeFrame: Up to 15 years
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Bouthaina S Dabaja
role: PRINCIPAL_INVESTIGATOR
References: